Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 2, 2014, Pages 406-415

  Murray, Louise J ^a,b   Lilley, John ^a   Thompson, Christopher M ^a   Cosgrove, Vivian ^a   Mason, Josh ^a,b   Sykes, Jonathan ^a   Franks, Kevin ^a   Sebag Montefiore, David ^a,b   Henry, Ann M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; TRANSMISSION CONTROL PROTOCOL;

DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING; DYNAMIC CONTRAST ENHANCED; INTRAPROSTATIC LESIONS; METHODS AND MATERIALS; NORMAL TISSUE COMPLICATION PROBABILITIES; PLANNING TARGET VOLUMES; TUMOR CONTROL PROBABILITY; VOLUMETRIC MODULATED ARC THERAPY;

UROLOGY;

GADOTERATE MEGLUMINE; GADOTERIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOMINANT INTRAPROSTATIC LESION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LESIONS AND DEFECTS; MALE; NORMAL TISSUE COMPLICATION PROBABILITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE VOLUME; RADIATION DOSE; RADIOLOGICAL PARAMETERS; SENSITIVITY ANALYSIS; STEREOTACTIC ABLATIVE RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR CONTROL PROBABILITY; VOLUMETRIC MODULATED ARC THERAPY; VOLUMETRY;

CONTRAST MEDIA; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMUR HEAD; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGANS AT RISK; PROBABILITY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; SEMINAL VESICLES; TUMOR BURDEN; URETHRA; URINARY BLADDER;

EID: 84899980717     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.01.042     Document Type: Article

References (37)

1. J.O. Barentsz, J. Richenberg, and R. Clements et al. ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 746 757
2. N. Cellini, A.G. Morganti, and G.C. Mattiucci et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiation therapy: Implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 595 599
3. G. Bauman, M. Haider, and U.A. Van der Heide et al. Boosting imaging defined dominant prostatic tumors: A systematic review Radiother Oncol 107 2013 274 281
4. D. Pucar, H. Hricak, and A. Shukla-Dave et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence Int J Radiat Oncol Biol Phys 69 2007 62 69
5. D.J. D'Ambrosio, A. Pollack, and E.E. Harris et al. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 70 2008 671 677
6. J.H. Chang, D. Lim Joon, and S.T. Lee et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using (1) (1)C-choline positron emission tomography scans Int J Radiat Oncol Biol Phys 83 2012 e691 e696
7. N. Housri, H. Ning, and J. Ondos et al. Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer Int J Radiat Oncol Biol Phys 80 2011 614 620
8. J. Seppala, M. Seppanen, and E. Arponen et al. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer Radiother Oncol 93 2009 234 240
9. C.M. Nutting, C.M. Corbishley, and B. Sanchez-Nieto et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: Dose escalation of pathologically identified tumour nodules using intensity modulated radiation therapy Br J Radiol 75 2002 151 161
10. P. Xia, B. Pickett, and E. Vigneault et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy Int J Radiat Oncol Biol Phys 51 2001 244 254
11. R. Azzeroni, A. Maggio, and C. Fiorino et al. Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): Sensitivity to TCP parameters Phys Med 29 2013 592 598
12. I.M. Lips, U.A. van der Heide, and K. Haustermans et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial Trials 12 2011 255
13. A. Maggio, C. Fiorino, and P. Mangili et al. Feasibility of safe ultra-high (EQD (2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by helical tomotheraphy Acta Oncol 50 2011 25 34
14. J.F. Fowler The radiobiology of prostate cancer including new aspects of fractionated radiotherapy Acta Oncol 44 2005 265 276
15. P.S. Tofts, G. Brix, and D.L. Buckley et al. Estimating kinetic parameters from dynamic contrast-enhanced T (1)-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232
16. A. Nahum, and B. Sanchez-Nieto Tumour control probability modelling: Basic principles and applications in treatment planning Phys Med 17 suppl 2 2001 S11
17. J. Uzan, and A.E. Nahum Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite Br J Radiol 85 2012 1279 1286
18. J.T. Lyman Complication probability as assessed from dose-volume histograms Radiat Res Suppl 8 1985 S13 S19
19. G.J. Kutcher, and C. Burman Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method Int J Radiat Oncol Biol Phys 16 1989 1623 1630
20. A. Niemierko Reporting and analyzing dose distributions: A concept of equivalent uniform dose Med Phys 24 1997 103 110
21. J.M. Michalski, H. Gay, and A. Jackson et al. Radiation dose-volume effects in radiation-induced rectal injury Int J Radiat Oncol Biol Phys 76 suppl 3 2010 S123 S129
22. S.T. Peeters, M.S. Hoogeman, and W.D. Heemsbergen et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling Int J Radiat Oncol Biol Phys 66 2006 11 19
23. C.H. Tan, W. Wei, and V. Johnson et al. Diffusion-weighted MRI in the detection of prostate cancer: Meta-analysis AJR Am J Roentgenol 199 2012 822 829
24. P. Kozlowski, S.D. Chang, and E.C. Jones et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology J Magn Reson Imaging 24 2006 108 113
25. K.M. Selnaes, A. Heerschap, and L.R. Jensen et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: Unbiased cancer identification by matching to histopathology Invest Radiol 47 2012 624 633
26. C. Beltran, M.G. Herman, and B.J. Davis Planning target margin calculations for prostate radiotherapy based on intrafraction and interfraction motion using four localization methods Int J Radiat Oncol Biol Phys 70 2008 289 295
27. K.M. Langen, T.R. Willoughby, and S.L. Meeks et al. Observations on real-time prostate gland motion using electromagnetic tracking Int J Radiat Oncol Biol Phys 71 2008 1084 1090
28. M. van Herk, P. Remeijer, and C. Rasch et al. The probability of correct target dosage: Dose-population histograms for deriving treatment margins in radiotherapy Int J Radiat Oncol Biol Phys 47 2000 1121 1135
29. Franzen LWA. Phase III study of hypofractionated radiotherapy of intermediate risk localised prostate cancer. Version 6.0. ISRCTN45905321. 2011; Available at: http://www.controlled-trials.com/ISRCTN45905321. Accessed March 1st, 2013.
30. J.P. Kirkpatrick, D.J. Brenner, and C.G. Orton Point/counterpoint. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery Med Phys 36 2009 3381 3384
31. A.E. Nahum, and J. Uzan (Radio)biological optimization of external-beam radiotherapy Comput Math Methods Med 2012 2012 329214
32. V. Fonteyne, G. Villeirs, and B. Speleers et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion Int J Radiat Oncol Biol Phys 72 2008 799 807
33. G. Groenendaal, M. van Vulpen, and S.R. Pereboom et al. The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy Radiother Oncol 103 2012 233 238
34. M.K. Buyyounouski, R.A. Price Jr., and E.E. Harris et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Co mmittee Int J Radiat Oncol Biol Phys 76 2010 1297 1304
35. Dearnaley D. CHHIP trial physics plan assessment form. 2006. Available at: http://rttrialsqa.dnsalias.org/chhip/ CHHIP%20Physics%20Plan%20Assessment%20Form%20v4%5B1%5D.0.pdf. Accessed June 25th, 2012.
36. van As N. The PACE study: International Randomized Study of Laparoscopic Prostatectomy vs Robotic Radiosurgery and Conventionally Fractionated Radiotherapy vs Radiosurgery for Early Stage Organ-Confined Prostate Cancer Trial protocol. 2012. Available at: http://public.ukcrn.org.uk/search/ StudyDetail.aspx?StudyID=12628. April 17th, 2013.
37. C. Burman, G.J. Kutcher, and B. Emami et al. Fitting of normal tissue tolerance data to an analytic function Int J Radiat Oncol Biol Phys 21 1991 123 135